Skip to main content

Johnson Matthey to exit battery materials

Following a detailed review, Johnson Matthey has concluded that the potential returns from its Battery Materials business “will not be adequate to justify further investment”. It will therefore seek to sell all or parts of the business.

Although demand has been growing strongly, the company said, “so is competition from alternative technologies and other manufacturers” and the market is becoming commoditised. JM had explored partnerships in the field but found that “our capital intensity is too high compared with other more established large-scale, low-cost producers”.

JM, Swan in battery partnership

Johnson Matthey, Thomas Swan and the UK’s Centre for Process Innovation (CPI) have teamed up in the ICE-Batt project. This seeks how to optimise battery technology by using innovative forms of carbon to overcome some of the limitations of lithium-ion batteries, including energy density, power density and low temperature performance.

JM to exit pharma?

In a pre-close trading update for the financial year ended 31 March 2021, Johnson Matthey (JM) CEO Robert MacLeod revealed that: “We have commenced a strategic review of Health, as we continue to focus resources to maximise value for our shareholders”.

Full results will be announced on 27 May but it is known that Health, which offers API custom manufacturing services, controlled substances, catalysts and generics, generated sales of £223 million, about 5% of the total sale. The division’s full-year operating performance is expected to be above the prior year.

JM buys from 3M

Johnson Matthey has acquired the full IP rights to a portfolio of silicon alloy-based anode materials for battery cells from 3M.
Subscribe to Johnson Matthey